Bayer acquires exclusive rights to Bioton’s insulin SciLin

10-Jul-2009 - China

Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton’s Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acquires the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin® in China. The contract and payment guarantee the exclusive commercial delivery of this recombinant insulin to Bayer in China with a secured supply of the product for the next 15 years.

“Through the planned distribution of SciLin®, we will further supply patients suffering from diabetes, and will expand our position in this very promising growth market,” said Andreas Fibig, CEO of Bayer Schering Pharma AG.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances